SNY
Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 52.33$. Average daily volumn in 3 months 2.48M. Market cap 124.97B
Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD Lastest price : 50.04$. Total volume : 2.23M. Market state PRE Click reload if you want to check the lastest price on market!!!
Sanofi (SNY)
Last Price
50.04$Change
-0.14Volume
2.23M
| Previous Close | 50.18 |
| Open | 49.85 |
| Day Range | 49.57-50.11 |
| Bid | 0.00 x 3k |
| Ask | 0.00 x 800 |
| Volume | 2.23M |
| Average Volume | 2.48M |
| Market Cap | 124.97B |
| Beta | 0.36 |
| 52 Week Range | 46.93-58.10 |
| Trailing P/E | 18.06 |
| Foward P/E | 11.19 |
| Dividend (Yield %) | 3.48% |
| Ex-Dividend Date | 2022-05-26 |
Financial Details
Organization
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Market Cap:
124.97BRevenue:
39.17BTotal Assets:
120.24BTotal Cash:
10.1B
News about "Sanofi"
Skyhawk strikes a $2.5B collaboration deal with Sanofi
Source from : The Business Journals - 23 hours ago
RNA startup Skyhawk Therapeutics has added another big name to its nest of partners: Sanofi ADR. Sanofi (Nasdaq: SNY) is paying the Waltham biotech $54 million up front and up to $2 billion or more in ...See details»
Sanofi jumpÂstarts efÂfort to supÂply 30 'essenÂtial' drugs to lowÂer-inÂcome counÂtries
Source from : ENDPOINTS NEWS - 1 days ago
A week after Sanofi promised to cut insulin prices, the pharma giant's nonprofit unit has agreed to make the life-saving drug and 29 others available to 40 lower-income countries. Together, the ...See details»
Sanofi launches global health brand with non-profit treatments
Source from : Reuters - 3 days ago
French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its ...See details»
BRIEF—C4X Discovery receives first milestone payment from Sanofi
Source from : The Pharma Letter - 9 hours ago
C4X Discovery Holdings, a pioneering UK drug discovery company, today announced that it has received a milestone payment of 3 million euros ($3.1 million) from Sanofi under the interleukin (IL)-17A ...See details»
FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects
Source from : BioPharma Dive - 7 days ago
Liver problems in trial volunteers led the agency to curtail studies of the drug, marking the second major setback related to Sanofi’s acquisition of Principia Biopharma.See details»
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
Source from : YAHOO!Finance - 6 days ago
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.See details»
Bill Haney's latÂest startÂup scores deal from Sanofi, its newest Big PharÂma partÂner, with $54M upÂfront
Source from : ENDPOINTS NEWS - 1 days ago
A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist. Skyhawk Therapeutics, the biotech headed by serial entrepreneur and ...See details»
Sanofi makes key treatments available on non-profit basis in lower-income countries
Source from : The Financial Express on MSN.com - 2 days ago
The countries involved are mainly in Africa, from Niger to Zimbabwe. Conflict-hit countries such as Syria are also part of the initiative, as well as some Asian countries including Cambodia and ...See details»
Sanofi's flu shots licensed & approved for the U.S. 2022-2023 influenza season
Source from : Seeking Alpha - 5 days ago
Sanofi (SNY) on Friday said the U.S. FDA had licensed and approved its influenza vaccines for use in the 2022-2023 flu season.The vaccines approved include SNY's ...See details»
Why Sanofi is investing in health care ecosystems
Source from : Devex - 3 days ago
Sanofi's global health unit, launched in 2021, announced on Monday a new brand and fund that will be supporting its goal to bring 30 essential medicines to 40 lower-income countries.See details»
Sanofi Global Health Launches Impact Brand For 30 Medicines In Low-income Countries
Source from : Nasdaq - 3 days ago
Sanofi Global Health (SNYNF, SNY) announced the launch of Impact, a new brand of standard of care medicines which includes insulin, glibenclamide and oxaliplatin, for distribution in low-income ...See details»
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
Source from : YAHOO!Finance - 2 days ago
Skyhawk Therapeutics, Inc. today announced the signing of an exclusive worldwide collaboration agreement with Sanofi to discover and develop novel small molecules that modulate RNA splicing for ...See details»
Sanofi, GSK Variant-specific COVID Shot Found Effective Against Omicron
Source from : International Business Times - 13 days ago
Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.See details»
Sanofi Launches Its First Digital Accelerator
Source from : healthcarepackaging - 2 days ago
Sanofi has announced the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company.See details»